0NFA) announces patent application covering several families of psilocin analogues
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aimed at transforming the treatment of mental health and addiction disorders, today announced that it has filed an application for full patent covering several families of psilocin analogues. According to the update, the app includes solutions to directly improve the accuracy of delivery control and shelf stabilization of psilocin, the active metabolite of psilocybin, both of which are essential for use in medical settings. . “The goal of creating these improved second generation compounds is to enable safer and more effective treatments for patients as well as better management of dosage and drug behavior for clinicians,” said the Scientific Director. Rob Roscow in the press release. “We believe these improvements are necessary for psychedelic drugs to become an accepted and adopted form of treatment. “
To view the full press release, visit https://ibn.fm/Bl1hn
About the Mydecine Innovations Group
Mydecine Innovations is a biotechnology and digital technology company that develops innovative first and second generation therapies for the treatment of mental health and addiction through world-class technology and drug development infrastructure. Mydecine was founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovation in mental health and therapeutic treatment environments. Mydecine Innovations Group is dedicated to the effective development of innovative therapies to treat PTSD, depression, anxiety, substance abuse and other mental health disorders. The company’s business model combines clinical trials and data findings, technology, and scientific and regulatory expertise with a focus on psychedelic therapy underpinned by other new molecules with differentiated therapeutic potential. By collaborating with some of the world’s largest authorities bound by best practice, Mydecine Innovations Group aims to responsibly accelerate the development of new medicines on its platforms, seeking to effectively treat and ultimately change the way mental health disorders. are processed. Mydecine’s vision is to bridge the current gap between what the mental health system currently provides and the needs of patients. Mydecine is headquartered in Denver, Colorado, USA, with international offices in Leiden, The Netherlands. For more information about the company, please visit www.Mydecine.com.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company newsroom at https://ibn.fm/MYCOF
PsychedelicNewsWire (PNW) is a specialty content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advancements of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly inform investors on important industry news, (3) relies on a team of expert editors to improve press releases for maximum impact, (4) help companies manage and optimize social media on a range of platforms, and (5) provides unprecedented business communication solutions. PNW keeps abreast of the latest information and has built a reputation as a go-to source for coverage of psychedelics, therapies and emerging market opportunities. Our team of seasoned journalists have a proven track record of helping public and private companies gain traction with a broad audience of investors, consumers, media and the general public by leveraging our extensive broadcast network of over 5,000 key syndication points. PNW is committed to providing enhanced brand visibility and recognition to companies operating in emerging psychedelic markets.
To receive instant SMS alerts, send “Groovy” to 21000 (US mobile phones only)
For more information, please visit https://www.PsychedelicNewsWire.com
Do you have any questions or are you interested in working with PNW? Ask our editor
San Francisco, California
PsychedelicNewsWire is part of the InvestorBrandNetwork.